Previous Article | Next Article ![]()
Infection and Immunity, February 2000, p. 960-964, Vol. 68, No. 2
Department of Vaccines, National Public
Health Institute,1 and Department of
Pathology, National Veterinary and Food Research
Institute,2 Helsinki, Finland
Received 6 May 1999/Returned for modification 21 July 1999/Accepted 9 November 1999
The role of gamma interferon (IFN- Chlamydia pneumoniae, the
most common chlamydial pathogen affecting humans, causes a rather mild
acute respiratory infection (14). It is probable that
C. pneumoniae infection, like other chlamydial infections,
can also result in chronic, persistent infection with several possible
disease outcomes, such as coronary heart disease (5, 22).
Chlamydia trachomatis is a prime example and a well-studied
pathogen causing pelvic inflammatory disease and trachoma
(2). In addition to animal models of these diseases, the
C. trachomatis mouse pneumonitis (MoPn) variant has been
used to study chlamydial pneumonia in mice. A mouse model has been developed also for C. pneumoniae (12, 27). For
both C. pneumoniae and C. trachomatis,
reinfection is common and no vaccines are available. In C. trachomatis MoPn and C. pneumoniae mouse models there
is clear evidence of protective immunity seen as a more rapid clearance
of bacteria in reinfection (4, 13), and the protective role
of T cells is apparent (18, 23). In the MoPn infection, both
CD4+ and CD8+ T cells have been reported to be
protective, with the role of CD4+ cells being more
important (10, 16, 25). Protective immunity against C. pneumoniae seems to be different: the importance of CD8+ cells has been demonstrated both in the clearance of
primary infection (20) and in protection against reinfection
(18), while CD4+ cells, in the absence of
CD8+ cells, may even enhance the bacterial growth in the
lungs (20).
The mechanism underlying the protection mediated by the
CD8+ cells in C. pneumoniae infection is still
unclear. Cytotoxic T lymphocytes (CTL) specific for C. trachomatis have been demonstrated in C. trachomatis-infected mice (1, 21). However, there is no
evidence of protective CTL activity against C. pneumoniae, and the course of primary infection is not altered in
perforin-deficient mice (20). CD8+ cells may
also function by secreting cytokines such as gamma interferon (IFN- In the present study, we therefore used the IFN- To neutralize IFN- At certain time points (in BALB/c mice, 6 and 12 days after primary
infection and reinfection, and in C57BL/6 mice, 6 and 12 days after
primary infection and 6 days after reinfection) 6 to 10 IFN- For histopathological scoring, the left lung that in mice consists of
only one lobe was fixed in 10% buffered formalin. The whole left lung
was cut transversely at an equidistance of 4 µm to three parts,
representing the cranial, middle, and caudal left lung. The tissue was
processed routinely, and the three parts were embedded in paraffin side
by side into the same block in such a way that the three complete cross
sections of the cranial, middle, and caudal lung could be evaluated on
the same section. The sections were stained with hematoxylin and eosin
and evaluated blindly under a light microscope by two pathologists.
The severity of pneumonia was described as minimal, mild, moderate,
marked, and severe, for which arbitrary scores of 0, 1, 2, 3, and 4 were respectively assigned. The C. pneumoniae-induced pneumonia is typically cranioventral in distribution, and in mild cases, pneumonic lesions are present only in the cranial part of the
lung. As the severity increases, the pneumonic area extends to the
middle lung, and in very severe cases, affects the whole lung. A
locally extensive pneumonia with changes only in one of the three
sections (the cranial part) affecting 10 to 50% of that section and
about 5 to 25% of the whole cross-sectional area of the left lung was
described as mild (1), and a nearly diffuse severe pneumonia
affecting all three cross sections and 75 to 100% of the total
cross-sectional area was described as severe (4). In
moderate pneumonia (2) there were pneumonic changes in two
cross sections affecting about 25 to 50% of the whole cross-sectional area of the lung. When there were changes in all three sections and
about 50 to 75% of the whole cross-sectional area showed lesions, the
pneumonia was described as marked (3). The differences between groups were tested with a nonparametric Mann-Whitney U test.
Mononuclear cells were isolated from mechanically homogenized lungs in
the primary infection experiments, as described previously (17). For the flow cytometric analysis, 0.4 × 106 mononuclear cells were stained with 5 µl of
phycoerythrin-conjugated anti-mouse mac-1/CD11b (M1/70.15) (Caltag,
South San Francisco, Calif.). Rat IgG2b was used as a control for
unspecific binding, and unstained cells were used for adjustment of
FACScan (Becton Dickinson, San Jose, Calif.). Secretion of tumor
necrosis factor alpha (TNF- Intranasal inoculation of untreated mice with C. pneumoniae
resulted in a self-restricted infection without any clinical symptoms in either BALB/c or C57BL/6 mice, as shown previously (17,
20). Primary infection of BALB/c mice peaked during the first 2 weeks at 104 IFU/lung and was cleared in a period of 3 to 4 weeks (Fig. 1A). The primary infection of
C57BL/6 mice peaked somewhat later in the second week, at approximately
105 IFU/lung, and was cleared in approximately 6 weeks
(Fig. 1A). Neutralization of IFN-
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Acquired Immunity to Chlamydia
pneumoniae Is Dependent on Gamma Interferon in Two Mouse Strains
That Initially Differ in This Respect after Primary Challenge

![]()
ABSTRACT
Top
Abstract
Text
References
) in a Chlamydia
pneumoniae mouse model was studied by in vivo neutralization in
two inbred mouse strains. During primary C. pneumoniae
infection, neutralization of IFN-
increased both the numbers of
bacteria and the pneumonia score in the lungs of C57BL/6 mice but not
BALB/c mice. During reinfection, the bacterial counts in the lungs were
increased by IFN-
neutralization in both mouse strains. Thus, the
effect of IFN-
neutralization was dependent on the genetic
background in primary infection. However, IFN-
appeared to be
equally important in both mouse strains during reinfection.
![]()
TEXT
Top
Abstract
Text
References
)
(7), and the protective role of C. trachomatis-specific CTLs has been reported to be dependent on
IFN-
production (15). The importance of IFN-
in
protection against C. trachomatis infection has been shown
by several methods (in vivo depletion, administration of recombinant
IFN-
, and use of genetically modified mice) (11, 19, 24).
C57BL/6 mice produce IFN-
in response to C. pneumoniae primary infection (20) in contrast to BALB/c mice, which do not (17). Thus, there appears to be strain-specific
differences in the importance of IFN-
. Studies using genetically
modified IFN-
R
/
knockout mice have also shown the
importance of IFN-
during C. pneumoniae infection in
C57BL/6 mice (20). IFN-
can be produced by several cell
types, and it participates in many development and activation steps of
different immune cells. Thus, the role of IFN-
, particularly in
acquired immunity, could not be studied by the knockout mouse approach,
since the genetic modification would likely affect both the development
of immunity in response to primary infection and its effect during
reinfection. By contrast, by in vivo neutralization of IFN-
by
specific antibodies, it is possible to target the deficiency on a
specific phase, i.e., either on the primary infection or on reinfection.
neutralization
method to evaluate the role of IFN-
in protection against either
C. pneumoniae primary infection or reinfection in BALB/c and
C57BL/6 mice. Monoclonal antibody to IFN-
was administered intraperitoneally prior to and during infection, and the effect was
evaluated using bacterial counts in the lungs and severity of pneumonia
as parameters.
, 6- to 8-week-old female BALB/cHsd (Laboratory
Animal Centre, University of Helsinki, Finland) and C57BL/6JBom (Bomholtgård Breeding and Research Centre Ltd., Ry, Denmark) mice were
injected intraperitoneally with 1-mg doses of anti-IFN-
monoclonal
antibody (clone XMG 1.2; a kind gift from R. L. Coffman, DNAX
Research Institute, Palo Alto, Calif.) that blocks biological activity
of IFN-
(3) 1 day before primary challenge or
rechallenge, depending on which one was targeted, and every third or
fourth day thereafter. IFN-
-neutralized and untreated control mice
were inoculated intranasally with 106 inclusion-forming
units (IFU) of a C. pneumoniae Kajaani 6 isolate in 40 µl
of sucrose-phosphate-glutamate solution under light carbon dioxide
(BALB/c) or Metofane (Pitman-Moore, Inc., Mundelein, Ill.) (C57BL/6)
anesthesia. Rechallenge was given similarly, when the mice had cleared
the primary infection (33 and 63 days after primary infection to BALB/c
and C57BL/6 mice, respectively [17, 20]). C. pneumoniae inoculation under Metofane anesthesia results in increased bacterial count (0.5 to 1 log) and pneumonia score in the
lungs, compared to CO2 anesthesia. The choice of anesthetic does not, however, influence the overall kinetics of infection or the
degree of protection detected during reinfection. Most importantly, the
immune mechanisms are not affected by the chosen anesthetic (our
unpublished data). Because the goal of this work was to assess
qualitative differences in the effect of IFN-
neutralization, rather
than comparison of quantitative differences, between the two mouse
strains, the usage of different anesthetics with the different mouse
strains most likely plays a minor role.
-neutralized and untreated mice were sacrificed. The
supernatants of mechanically homogenized right lungs were cultured on
Vero cell monolayers using centrifugation and cycloheximide, as
described previously (17). Intracellular inclusions were counted under a UV microscope from cells stained with fluorescein isothiocyanate-conjugated Chlamydia-specific antibodies
(Kallestad, Chaska, Minn.). The results are expressed as logarithmic
values of IFU per lung. After the dilution factors were taken into
account, one inclusion seen by microscopy corresponded to a
log10 value of 1 IFU/lung (the detection limit). If no
inclusions were detected, a log10 value of 0.5 was used for
calculating means and statistics (using Mann-Whitney U test). In
addition to the controls done in parallel with the IFN-
-neutralized
mice, accumulated culture data from several different primary infection
and reinfection experiments are presented as a reference for general
infection kinetics.
), interleukin 10 (IL-10), and IL-5 was
assessed with enzyme-linked immunosorbent assay from culture
supernatants of the mononuclear cells alone (background) or stimulated
with formalin-inactivated C. pneumoniae (1 µg/ml)
collected after 72 h incubation at 37°C in 5% CO2
atmosphere as described previously for IL-10 and TNF-
in references
17 and 18, respectively. In an
IL-5 enzyme-linked immunosorbent assay, 2 µg of anti-mouse and -human
IL-5 (TRFK5, rat IgG1; PharMingen, San Diego, Calif.) per ml was used
as first antibody, 1 µg of biotinylated anti-mouse IL-5 (TRFK4, rat
IgG2a; PharMingen) per ml was used as second antibody, and
recombinant mouse IL-5 (PharMingen) was used as a standard.
Results of the background control were subtracted from the final results.
prior to and during the primary
infection altered the bacterial counts in the lungs. In the BALB/c
strain, less bacteria were isolated from the IFN-
-neutralized mice
during the first week (on day 6 the P value was 0.01), but
during the second week of infection there was no difference between
IFN-
-neutralized and control mice (Fig. 1A). In contrast, the
numbers of bacteria were increased by a hundredfold in
anti-IFN-
-treated C57BL/6 mice at 12 days after primary C. pneumoniae infection (P = 0.003) (Fig. 1A).

View larger version (26K):
[in a new window]
FIG. 1.
Medians (bars) and upper and lower quartiles (error
bars) of C. pneumoniae culture results after primary
challenge (A) or rechallenge (B) (given 33 and 63 days after primary
challenge to BALB/c and C57BL/6 mice, respectively) with
106 IFU of C. pneumoniae are shown for
IFN-
-neutralized (white bars) and untreated (gray bars) BALB/c and
C57BL/6 mice. Data are from single experiments with 10 and 6 to 8 mice
per group at each time point in BALB/c and C57BL/6 strains,
respectively. In addition, accumulated data describing mean culture
results from several different experiments (resulting in 15 to 43 and
10 to 18 mice per time point in BALB/c and C57BL/6 strains,
respectively) are presented as a reference for general infection
kinetics in immunocompetent mice (line) (the data for BALB/c mice have
been described previously [17]). *, statistically
significant difference between IFN-
-neutralized mice and untreated
control mice, as evaluated by Mann-Whitney U test (P = 0.01 and 0.003 [A] and P = 0.002, 0.04, and
0.028 [B]); BD, below detection limit; ND, not determined.
The pneumonia score was significantly higher in IFN-
-neutralized
C57BL/6 mice on day 12 after primary infection than in untreated mice
(Table 1). The pulmonary inflammatory
infiltrate mainly consisted of macrophages and lesser numbers of
neutrophils and lymphocytes. In addition, in the IFN-
-neutralized
mice there were moderate numbers of multinucleated giant cells and
eosinophils, which were not present in the untreated mice. In BALB/c
mice there were no differences between the IFN-
-neutralized and
untreated mice (Table 1). However, the lower pneumonia score in BALB/c mice than in C57BL/6 mice was partly due to the anesthesia method (our
unpublished data).
|
The proportion of macrophages among the isolated pulmonary mononuclear
cells, determined by flow cytometric analysis, was increased in
IFN-
-neutralized C57BL/6 mice, in comparison to the untreated mice,
especially at 12 days after infection (33% versus 29% and 62% versus
21% at days 6 and 12, respectively). There were no differences in the
proportions of macrophages in the IFN-
-neutralized BALB/c mice
versus controls (13% versus 16% and 10% versus 9%, at days 6 and
12, respectively). The pulmonary mononuclear cells isolated from
IFN-
-neutralized C57BL/6 mice at 12 days after infection expressed
increased (by 330 pg/ml) C. pneumoniae-induced TNF-
production, compared to the untreated mice. In BALB/c mice, the TNF-
production was reduced by 260 pg/ml in cells from IFN-
-neutralized
mice, compared to control. IFN-
neutralization did not result in
increased IL-10 or IL-5 production in response to C. pneumoniae stimulation in either of the mouse strains (data not shown).
In both mouse strains, significant protection was acquired after
primary infection, as shown previously (17, 20). During subsequent reinfection, less bacteria could be cultured and the infection was cleared in approximately 2 (BALB/c) and 3 (C57BL/6) weeks
(Fig. 1B). The neutralization of IFN-
resulted in a significant increase of the bacterial burden during reinfection (P
values of 0.002 and 0.028 at day 6 in BALB/c and C57BL/6 mice,
respectively, and a P value of 0.04 at day 12 in BALB/c
mice) (Fig. 1B). The pneumonia score was higher in the
IFN-
-neutralized C57BL/6 mice, but the difference was not
statistically significant (Table 1). Again, no differences were
detected in the pneumonia scores of BALB/c mice (Table 1).
The effect of anti-IFN-
antibody treatment during primary infection
differed between the two mouse strains studied; neutralization of
IFN-
exacerbated the infection only in C57BL/6 mice. The differences in the effect of IFN-
neutralization indicate the effect of genetic background on the initial immunity, as seen during primary infection. Macrophages have been shown to be able to produce IFN-
in response to, for example, mycobacterial stimulation (8a). Thus,
IFN-
production by macrophages may be one factor affecting the type of initial immunity in the two mouse strains. Different inbred mouse
strains have been shown to develop different types of immune responses
during many intracellular infections, and this is often reflected in
differences in their susceptibilities to infection (9, 26).
It is interesting that although BALB/c mice appear not to be dependent
on IFN-
during primary C. pneumoniae infection, they do
not develop a typical Th2 type response either, since no increment in
IL-10 or IL-5 production was detected even after IFN-
neutralization. Since the in vivo neutralization technique probably did
not lead to a total deficiency of IFN-
, it may be that clearance of
primary C. pneumoniae infection in BALB/c mice is either
IFN-
independent or only very small amounts of IFN-
are needed.
In BALB/c mice, lesser numbers of bacteria were recovered from the
lungs of IFN-
-deficient mice than control mice at 6 days after
infection. This effect could be a demonstration of the efficacy of
IFN-
-independent mechanisms in naive BALB/c mice. Neutralization of
IFN-
increased the number of macrophages and the production of
TNF-
in the mononuclear cell fraction isolated from the lungs of
C57BL/6 mice. IFN-
neutralization increased the severity of
pneumonia in C57BL/6 mice but not in BALB/c mice. In addition,
multinucleated giant cells were present in the lungs of
IFN-
-neutralized C57BL/6 mice. These cells are usually formed by
fusion of epithelioid cells or immature macrophages after, for example,
long-lasting stimulation by T cells and/or ineffective processing of
intracellular bacteria (8). In our infection model, it may
be that neutralization of IFN-
had a negative effect on macrophage function.
The present findings during primary infection are in good accordance
with previous data showing an IFN-
-independent cellular response in
BALB/c mice (17), while C57BL/6 mice have been shown to be
dependent on IFN-
-mediated protection mechanisms (20). During reinfection, a Th1 type immune response has been detected also
in BALB/c mice (17), and accordingly, neutralization of IFN-
exacerbated the infection in both mouse strains. A similar exacerbation of C. pneumoniae reinfection by IFN-
neutralization is also seen in outbred NIH/S mice (our unpublished
data). As we have shown earlier that the acquired immunity in BALB/c
mice is dependent on CD8+ cells (18), the
results of this study suggest that they may at least partially function
through IFN-
production. However, actively IFN-
-producing cells
have also been demonstrated in CD8-depleted mice, in which the acquired
immunity seen during reinfection is abolished (18); thus,
IFN-
alone is probably not the only effector mechanism in acquired
immunity. In conclusion, these results suggest that the importance of
IFN-
during primary C. pneumoniae infection depends on
the genetic background of the mouse. However, in acquired immunity,
detected during reinfection, the importance of IFN-
overrides the
initial differences.
| |
ACKNOWLEDGMENTS |
|---|
This study was partially supported by the Academy of Finland (grant number 8400) and contract number BIO-CT96-0152 of the Biotechnology Programme of the Commission of the European Union.
We thank Outi Rautio, Irene Viinikangas, and Leena Erkkilä for skillful technical assistance.
| |
FOOTNOTES |
|---|
* Corresponding author. Present address: Cultor Corporation, Technology Center, FIN-02460 Kantvik, Finland. Phone: 358-9-297 4512. Fax: 368-9-298 2203. E-mail: nina.rautonen{at}cultor.fi.
Previously published as Jenni M. Penttilä.
Editor: R. N. Moore
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Beatty, P. R., and R. S. Stephens. 1994. CD8+ T lymphocyte-mediated lysis of Chlamydia-infected L cells using an endogenous antigen pathway. J. Immunol. 153:4588-4595[Abstract]. |
| 2. |
Beatty, W. L.,
R. P. Morrison, and G. I. Byrne.
1994.
Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis.
Microbiol. Rev.
58:686-699 |
| 3. |
Cherwinski, H. M.,
J. H. Schumacher,
K. D. Brown, and T. R. Mosmann.
1987.
Two types of mouse helper T cell clone III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays and monoclonal antibodies.
J. Exp. Med.
166:1229-1244 |
| 4. | Coalson, J. J., V. T. Winter, L. B. Bass, J. Schachter, B. G. Grubbs, and D. M. Williams. 1987. Chlamydia trachomatis pneumonia in the immune, athymic and normal BALB mouse. Br. J. Exp. Pathol. 68:399-411[Medline]. |
| 5. | Danesh, J., R. Collins, and R. Peto. 1997. Chronic infections and coronary heart disease: is there a link? Lancet 350:430-436[CrossRef][Medline]. |
| 6. | Darville, T., C. W. Andrews, Jr., K. K. Laffoon, W. Shymasani, L. R. Kishen, and R. G. Rank. 1997. Mouse strain-dependent variation in the course and outcome of chlamydial genital tract infection is associated with differences in host response. Infect. Immun. 65:3065-3073[Abstract]. |
| 7. | Dong, Z., M. D. Edelstein, and L. J. Glickstein. 1997. CD8+ T cells are activated during the early Th1 and Th2 immune responses in a murine Lyme disease model. Infect. Immun. 65:5334-5337[Abstract]. |
| 8. | Fais, S., V. L. Burgio, M. R. Capobianchi, S. Gessani, F. Pallone, and F. Belardelli. 1997. The biological relevance of polykaryons in the immune response. Immunol. Today 18:522-527[CrossRef][Medline]. |
| 8a. | Fenton, M. J., M. W. Vermeulen, S. Kim, M. Burdick, R. M. Strieter, and H. Kornfeld. 1997. Induction of gamma interferon production in human alveolar macrophages by Mycobacterium tuberculosis. Infect. Immun. 65:5149-5156[Abstract]. |
| 9. |
Heinzel, F. P.,
M. D. Sadick,
B. J. Holaday,
R. L. Coffman, and R. M. Locksley.
1989.
Reciprocal expression of interferon or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets.
J. Exp. Med.
169:59-72 |
| 10. |
Igietseme, J. U.,
D. M. Magee,
D. M. Williams, and R. G. Rank.
1994.
Role for CD8+ T cells in antichlamydial immunity defined by Chlamydia-specific T-lymphocyte clones. 1994.
Infect. Immun.
62:5195-5197 |
| 11. |
Johansson, M.,
K. Schön,
M. Ward, and N. Lycke.
1997.
Studies in knockout mice reveal that anti-chlamydial protection requires Th1 cells producing IFN- : is this true for humans?
Scand. J. Immunol.
46:546-552[CrossRef][Medline].
|
| 12. | Kaukoranta-Tolvanen, S.-S., A. L. Laurila, P. Saikku, M. Leinonen, L. Liesirova, and K. Laitinen. 1993. Experimental infection of Chlamydia pneumoniae in mice. Microb. Pathog. 15:293-302[CrossRef][Medline]. |
| 13. | Kaukoranta-Tolvanen, S.-S., A. L. Laurila, P. Saikku, M. Leinonen, and K. Laitinen. 1995. Experimental Chlamydia pneumoniae infection in mice: effect of reinfection and passive immunization. Microb. Pathog. 18:279-288[CrossRef][Medline]. |
| 14. | Kuo, C.-C., L. A. Jackson, L. A. Campbell, and J. T. Grayston. 1995. Chlamydia pneumoniae (TWAR). Clin. Microbiol. Rev. 8:451-461[Abstract]. |
| 15. |
Lampe, M. F.,
C. B. Wilson,
M. J. Bevan, and M. N. Starnbach.
1998.
Gamma interferon production by cytotoxic T lymphocytes is required for resolution of Chlamydia trachomatis infection.
Infect. Immun.
66:5457-5461 |
| 16. | Magee, D. M., D. M. Williams, J. G. Smith, C. A. Bleicker, B. G. Grubbs, J. Schachter, and R. G. Rank. 1995. Role of CD8 T cells in primary Chlamydia infection. Infect. Immun. 63:516-521[Abstract]. |
| 17. |
Penttilä, J. M.,
M. Anttila,
M. Puolakkainen,
A. Laurila,
K. Varkila,
M. Sarvas,
P. H. Mäkelä, and N. Rautonen.
1998.
Local immune responses to Chlamydia pneumoniae in the lungs of BALB/c mice during primary infection and reinfection.
Infect. Immun.
66:5113-5118 |
| 18. | Penttilä, J. M., M. Anttila, K. Varkila, M. Puolakkainen, M. Sarvas, P. H. Mäkelä, and N. Rautonen. 1999. Depletion of CD8+ cells abolishes memory in acquired immunity against Chlamydia pneumoniae in BALB/c mice. Immunology 97:490-496[CrossRef][Medline]. |
| 19. |
Rank, R. G.,
K. H. Ramsey,
E. A. Pack, and D. M. Williams.
1992.
Effect of gamma interferon on resolution of murine chlamydial genital infection.
Infect. Immun.
60:4427-4429 |
| 20. |
Rottenberg, M. E.,
A. C. G. Rothfuchs,
D. Gigliotti,
C. Svanholm,
L. Bandholtz, and H. Wigzell.
1999.
Role of innate and adaptive immunity in the outcome of primary infection with Chlamydia pneumoniae, as analyzed in genetically modified mice.
J. Immunol.
162:2829-2836 |
| 21. | Starnbach, M. N., M. J. Bevan, and M. F. Lampe. 1994. Protective cytotoxic T lymphocytes are induced during murine infection with Chlamydia trachomatis. J. Immunol. 153:5183-5189[Abstract]. |
| 22. | Taylor-Robinson, D., and B. J. Thomas. 1998. Chlamydia pneumoniae in arteries: the facts, their interpretation, and future studies. J. Clin. Pathol. 51:793-797[Medline]. |
| 23. | Williams, D. M., J. Schachter, D. J. Drutz, and C. V. Sumaya. 1981. Pneumonia due to Chlamydia trachomatis in the immunocompromised (nude) mouse. J. Infect. Dis. 143:238-241[Medline]. |
| 24. |
Williams, D. M.,
G. I. Byrne,
B. Grubbs,
T. J. Marshal, and J. Schachter.
1988.
Role in vivo for gamma interferon in control of pneumonia caused by Chlamydia trachomatis in mice.
Infect. Immun.
56:3004-3006 |
| 25. | Williams, D. M., B. G. Grubbs, E. Pack, K. Kelly, and R. G. Rank. 1997. Humoral and cellular immunity in secondary infection due to murine Chlamydia trachomatis. Infect. Immun. 65:2876-2882[Abstract]. |
| 26. |
Yang, X.,
K. T. HayGlass, and R. C. Brunham.
1996.
Genetically determined differences in IL-10 and IFN- responses correlate with clearance of Chlamydia trachomatis mouse pneumonitis infection.
J. Immunol.
156:4338-4344[Abstract].
|
| 27. |
Yang, Z.-P.,
C.-C. Kuo, and J. T. Grayston.
1993.
A mouse model of Chlamydia pneumoniae strain TWAR pneumonitis.
Infect. Immun.
61:2037-2040 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|